-
公开(公告)号：US11266606B2
公开(公告)日：2022-03-08
申请号：US16584170
申请日：2019-09-26
Inventor： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Minglin Ma , Robert S. Langer , Daniel G. Anderson
IPC: A61K35/39 , A61K9/00 , A61K9/50 , A61L29/08 , A61L31/10 , C08B37/00 , C12N5/00 , C12N5/071 , A61L33/08
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
-
公开(公告)号：US20210363540A1
公开(公告)日：2021-11-25
申请号：US17374497
申请日：2021-07-13
Applicant: Massachusetts Institute of Technology
Inventor： Daniel G. Anderson , Robert Alexander Wesselhoeft , Piotr S. Kowalski
Abstract: Methods and constructs for engineering circular RNA are disclosed. In some embodiments, the methods and constructs comprise a vector for making circular RNA, the vector comprising the following elements operably connected to each other and arranged in the following sequence: a.) a 5′ homology arm, b.) a 3′ group I intron fragment containing a 3′ splice site dinucleotide, c.) optionally, a 5′ spacer sequence, d.) a protein coding or noncoding region, e.) optionally, a 3′ spacer sequence, f.) a 5′ Group I intron fragment containing a 5′ splice site dinucleotide, and g.) a 3′ homology arm, the vector allowing production of a circular RNA that is translatable or biologically active inside eukaryotic cells. Methods for purifying the circular RNA produced by the vector and the use of nucleoside modifications in circular RNA produced by the vector are also disclosed.
-
公开(公告)号：US20210338789A1
公开(公告)日：2021-11-04
申请号：US17198037
申请日：2021-03-10
Inventor： Omar F. Khan , Jasdave S. Chahal , Daniel G. Anderson , Hidde Ploegh , Robert S. Langer , Tyler E. Jacks , David A. Canner
IPC: A61K39/00 , A61K31/713 , A61K39/12 , C12N15/87 , A61K48/00 , A61K39/002 , A61K9/00 , C12N15/88 , A61K39/145 , A61K9/51
Abstract: Compositions and methods for modified dendrimer nanoparticle (“MDNP”) delivery of therapeutic, prophylactic and/or diagnostic agent such as large repRNA molecules to the cells of a subject have been developed. MDNPs efficiently drive proliferation of antigen-specific T cells against intracellular antigen, and potentiate antigen-specific antibody responses. MDNPs can be multiplexed to deliver two or more different repRNAs to modify expression kinetics of encoded antigens and to simultaneous deliver repRNAs and mRNAs including the same UTR elements that promote expression of encoded antigens.
-
公开(公告)号：US10941395B2
公开(公告)日：2021-03-09
申请号：US16029273
申请日：2018-07-06
Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventor： Hao Yin , Wen Xue , Daniel G. Anderson , Joseph R. Dorkin , Tyler E. Jacks
Abstract: The present disclosure relates to compositions and methods for modifying a gene sequence, and for systems for delivering such compositions. For example, the disclosure relates to modifying a gene sequence using a CRISPR-Cas9 or other nucleic acid editing system, and methods and delivery systems for achieving such gene modification, such as viral or non-viral delivery systems.
-
公开(公告)号：US10709818B2
公开(公告)日：2020-07-14
申请号：US15341110
申请日：2016-11-02
Inventor： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Minglin Ma , Robert S. Langer , Daniel G. Anderson
IPC: A61L29/08 , A61K47/36 , A61K9/48 , A61K35/39 , C08B37/00 , A61K9/00 , A61K9/50 , A61L31/10 , A61L33/08 , C07D487/04 , C12N5/00 , C12N5/071
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
-
Patent Agency Ranking
公开(公告)号：US20190184067A1
公开(公告)日：2019-06-20
申请号：US16289390
申请日：2019-02-28
Inventor： Arturo Vegas , Joshua C. Doloff , Omid Veiseh , Minglin Ma , Robert S. Langer , Daniel G. Anderson
IPC: A61L29/08 , A61K47/36 , C12N5/071 , C07D487/04 , C12N5/00 , A61K9/00 , A61K9/48 , A61L31/10 , A61L33/08 , C08B37/00 , A61K35/39 , A61K9/50
CPC classification number: A61L29/085 , A61K9/0024 , A61K9/4816 , A61K9/5036 , A61K35/39 , A61K47/36 , A61L31/10 , A61L33/08 , C07D487/04 , C08B37/0084 , C12N5/0012 , C12N5/0677
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
-
公开(公告)号：US10172791B2
公开(公告)日：2019-01-08
申请号：US14776639
申请日：2014-03-14
Inventor： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup , Arturo Jose Vegas
Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
公开(公告)号：US09972649B2
公开(公告)日：2018-05-15
申请号：US15294914
申请日：2016-10-17
Applicant: Massachusetts Institute of Technology
Inventor： Virginia Spanoudaki , Daniel G. Anderson , Robert S. Langer
IPC: H01L27/146 , H01L29/06
CPC classification number: H01L27/14616 , G01T1/2018 , G01T1/241 , G01T1/247 , H01L27/14605 , H01L27/14636 , H01L29/0669
Abstract: A sensor comprises a substrate; an array of nanowire field effect transistors (NWFETs) formed in said substrate, each of the NWFETs having source, drain and gate terminals; a nanowire coupled between the source terminal and the drain terminal of each NWFET; and a layer of radiation sensitive material disposed over said NWFETs and said nanowires with each of the source, drain and gate terminals configured to be coupled to respective ones of first, second or third reference potentials, wherein each NWFET is configured such that the conductivity between the source and drain changes in response to radiation absorbed in the layer of radiation sensitive material such that the sensor generates an output signal in response to radiation absorbed by the radiation sensitive material.
-
公开(公告)号：US20180117216A1
公开(公告)日：2018-05-03
申请号：US15341118
申请日：2016-11-02
Inventor： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Robert S. Langer , Daniel G. Anderson
CPC classification number: A61L27/3804 , A61K9/0051 , A61K35/12 , A61K35/36 , A61K38/02 , A61L27/04 , A61L27/10 , A61L27/16 , A61L27/18 , A61L27/20 , A61L27/34 , A61L27/3813 , A61L27/3839 , A61L27/54 , A61L27/56 , A61L29/14 , A61L2300/252 , A61L2300/254 , A61L2400/18 , C08J7/12
Abstract: Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
-
公开(公告)号：US20180092850A1
公开(公告)日：2018-04-05
申请号：US15831570
申请日：2017-12-05
Inventor： Daniel G. Anderson , Robert S. Langer , Tram T. Dang
IPC: A61K9/16 , C12N5/071 , A61K9/00 , A61K31/573 , A61K45/06 , A61K35/39 , G01N33/50 , A61L27/38 , A61L27/48 , A61L27/54 , A61L27/52 , C08L5/04 , C08L5/08
CPC classification number: A61K9/1641 , A61K9/0019 , A61K31/573 , A61K35/39 , A61K45/06 , A61L27/3804 , A61L27/48 , A61L27/52 , A61L27/54 , A61L2300/41 , A61L2300/622 , A61L2300/64 , C12N5/0676 , C12N2502/1157 , C12N2533/40 , C12N2533/74 , G01N33/5088 , A61K2300/00 , C08L5/04 , C08L5/08
Abstract: A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
-
-
-
-
-
-
-
-
Search Results
104
records
(took 0.083 seconds)
